Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | BRD4 | O60885 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MYC | P01106 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29453524 | 0.95 | ALDH1A1 (0.56) | ALDH1A1LMNANR4A2KMT2AMEN1 | |
| SCHEMBL12281356 | 0.91 | ALDH1A1 (0.50) | ALDH1A1LMNANR4A2KMT2AMEN1 | |
| SCHEMBL2553966 | 0.91 | ALDH1A1 (0.50) | ALDH1A1LMNANR4A2KMT2AMEN1 | |
| SCHEMBL11926706 | 0.87 | MYC (0.66) | ALDH1A1LMNANR4A2KMT2AMEN1 | |
| SCHEMBL18624220 | 0.86 | MAPT (0.56) | ALDH1A1LMNANR4A2KMT2AMEN1 | |
| SCHEMBL14656964 | 0.85 | NR4A2 (0.51) | ALDH1A1LMNANR4A2KMT2AMEN1 | |
| SCHEMBL13352635 | 0.85 | NR4A2 (0.48) | ALDH1A1LMNANR4A2KMT2AMEN1 | |
| SCHEMBL18639316 | 0.85 | ALDH1A1 (0.53) | ALDH1A1LMNANR4A2KMT2AMEN1 | |
| SCHEMBL12282047 | 0.85 | NR4A2 (0.48) | ALDH1A1LMNANR4A2KMT2AMEN1 | |
| SCHEMBL14666395 | 0.84 | MYC (0.59) | ALDH1A1LMNANR4A2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422287-B2 | Bridged triarylamines and -phosphines as materials for electronic devices | MERCK PATENT GMBH (DE) | 2016-08-23 | — | — | US | disclosed |
| US-9422287-B2 | Bridged triarylamines and -phosphines as materials for electronic devices | MERCK PATENT GMBH (DE) | 2016-08-23 | — | — | US | disclosed |
| US-9422287-B2 | Bridged triarylamines and -phosphines as materials for electronic devices | MERCK PATENT GMBH (DE) | 2016-08-23 | — | — | US | disclosed |
| US-20130026422-A1 | BRIDGED TRIARYLAMINES AND -PHOSPHINES AS MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| US-20130026422-A1 | BRIDGED TRIARYLAMINES AND -PHOSPHINES AS MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| US-20130026422-A1 | BRIDGED TRIARYLAMINES AND -PHOSPHINES AS MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| WO-2011128017-A1 | BRIDGED TRIARYLAMINES AND -PHOSPHINES AS MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011128017-A1 | BRIDGED TRIARYLAMINES AND -PHOSPHINES AS MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130026422-A1 | BRIDGED TRIARYLAMINES AND -PHOSPHINES AS MATERIALS FOR ELECTRONIC DEVICES | TEC, PNMT, TES | ALDH1A1 612/4885LMNA 4237/4885NR4A2 2514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.